OGN Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Organon & Co.

Group 1 - The class action was filed on behalf of investors who purchased Organon & Co. securities between October 31, 2024, and April 30, 2025 [1] - Organon is a global healthcare company focused on improving women's health throughout their lives [1] - The allegations include misleading statements regarding Organon's capital allocation strategy, particularly its prioritization of regular quarterly dividends [2] Group 2 - The complaint claims that while promoting a strong capital allocation strategy, Organon concealed the high priority of its debt reduction strategy following the acquisition of Dermavant, leading to a 70% decrease in the regular quarterly dividend [3] - The truth was revealed on May 1, 2025, when Organon announced a significant reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price decline of over 27% [4] Group 3 - Shareholders interested in participating in the class action or serving as lead plaintiff are encouraged to contact the firm [5] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [6]